Evaxion Biotech Shows Progress Amid Nasdaq Challenges
Company Announcements

Evaxion Biotech Shows Progress Amid Nasdaq Challenges

Evaxion Biotech (EVAX) has released an update.

Evaxion Biotech reports significant progress in Q3 2024, highlighted by an expanded partnership with Merck and promising clinical results for its personalized cancer vaccine, EVX-01. Despite a cash position of $4.6 million and a net loss reduction, the company faces potential Nasdaq delisting due to equity compliance issues. Evaxion remains confident in its multi-partner strategy to drive future growth and income.

For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyEvaxion Biotech reports Q3 EPS (4c), consensus (31c)
TipRanks Auto-Generated NewsdeskEvaxion Biotech to Announce Q3 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App